Browse the evidence

High-calorie diets uncouple hypothalamic oxytocin (PVNOT) neurons from gut-derived CCK signaling via increased kappa-opioid tone and reduced CCKAR expression, rendering CCK ineffective at suppressing food intake.

If you are eating a high-calorie, high-fat/sugar diet, your body's natural ability to feel full from gut hormones like CCK is biologically suppressed. This is not a failure of willpower but a broken signal. To regain control, you must address the diet composition to potentially restore this pathway, or utilize interventions (like specific pharmacological combinations of OT and CCKAR agonists shown in the study) that bypass this block.

Selective activation of oxytocin-expressing PVN neurons (PVNOT) restores the ability of cholecystokinin (CCK) to suppress food intake in diet-induced obese mice.

This finding suggests that simply taking CCK might not work for obese individuals because their oxytocin pathway is disconnected. Future therapies might need to combine CCK with agents that activate oxytocin neurons or bypass this block to be effective.

Pharmacological inhibition of central aPKC activity acutely increases food intake and worsens glucose tolerance in chow-fed rodents.

Blocking a specific brain enzyme (aPKC) can cause immediate overeating and poor blood sugar control, even in lean animals. This underscores the importance of this enzyme in regulating hunger and metabolism.

Deletion of PKC-l in POMC neurons causes central leptin resistance, characterized by reduced melanocortin content and impaired leptin-induced neuronal activation.

Leptin resistance can be caused by defects in the downstream signaling of POMC neurons, specifically involving aPKC. This leads to reduced production of satiety signals (melanocortin), contributing to obesity.

GLP-1 receptor internalization is arrestin-independent and relies on a dual mechanism involving Gs/Gi/o protein activation, GRK phosphorylation, and both clathrin- and caveolae-mediated endocytosis.

This research clarifies that GLP-1 drugs work by engaging specific cellular recycling pathways (clathrin and caveolae) rather than the arrestin pathway. This mechanistic insight aids in designing drugs with optimized duration and fewer side effects, though it does not change immediate patient behavior.

Standardized Environmental, Social, and Governance (ESG) metrics for nutrition and health in the food and beverage sector are currently available but exhibit substantial heterogeneity in quality, domain coverage, and strength, limiting their ability to drive scalable public health impact.

For investors and policymakers, the current landscape of ESG nutrition metrics is fragmented. To drive real health outcomes, stakeholders must prioritize frameworks that use standardized, quantitative definitions of product healthfulness (e.g., using Nutrient Profiling Systems) and ensure equitable distribution of healthy foods. Simply having an ESG policy is insufficient; the metrics must be rigorous, verifiable, and aligned with scientific dietary guidelines.

Public awareness of the clinical success of anti-obesity medications (AOMs) does not reduce obesity stigma or shift public perception of obesity from a failure of willpower to a biological medical condition.

Health communicators and policymakers should not assume that highlighting the success of GLP-1 medications will automatically reduce obesity stigma. Since stigma is robustly linked to personal weight loss experiences and willpower beliefs, interventions must directly address these cognitive biases rather than relying on medical awareness alone.

Intensive lifestyle intervention (diet and exercise) does not significantly alter the rate of kidney function decline (eGFR slope) over 10 years in patients with type 2 diabetes and preserved baseline kidney function compared to usual care.

If you have type 2 diabetes and normal kidney function, an intensive lifestyle program focusing on weight loss and 175 minutes of weekly exercise will not significantly change the *rate* at which your kidney function declines over 10 years compared to standard diabetes care. However, it may help maintain a slightly higher average kidney function level, especially if your baseline function is already slightly reduced (eGFR <80). Focus on the overall health benefits rather than expecting a specific kidney outcome.

A remote, call-center-directed weight loss intervention combining diet and exercise counseling does not result in significant weight loss or improved cardiovascular risk factors in adult survivors of childhood acute lymphoblastic leukemia (ALL) compared to self-directed weight loss.

Standard remote weight loss programs are unlikely to succeed for adult survivors of childhood leukemia. Success requires tailoring to their specific health history, including managing pain and other treatment side effects, and likely involves more direct clinician involvement rather than purely remote coaching.

Circulating IGF-1 concentrations are not associated with all-cause, cardiovascular disease, or cancer-related mortality risk.

There is no evidence from this study that your natural IGF-1 levels predict your risk of death from cancer, heart disease, or other causes. You do not need to try to manipulate IGF-1 levels for longevity based on this data.

Loss-of-function mutations in the myostatin (MSTN) gene cause excessive skeletal muscle growth (hypertrophy) and increased strength by removing the natural inhibition on muscle development.

This paper describes a rare genetic condition (myostatin deficiency) that causes massive muscle growth. For the average person, this is not a viable or safe intervention. However, understanding that myostatin limits growth suggests that therapies blocking it (under medical supervision) might help those with muscle-wasting diseases, but it is not a recommendation for healthy individuals seeking hypertrophy.

Perivascular Fat Attenuation Index (FAI) measured via cardiac CT serves as a biomarker for coronary inflammation and predicts cardiac mortality, with values above -70.1 HU indicating a 6- to 9-fold higher adjusted risk of future cardiac mortality.

If you are getting a heart scan for chest pain, ask your doctor about the Fat Attenuation Index (FAI). This AI-enhanced measurement looks at the fat around your heart arteries to detect hidden inflammation. A high FAI score means your risk of a heart event is much higher, even if your arteries don't look blocked yet. This helps doctors treat you before a major problem occurs.

Semaglutide does not significantly impact renal outcomes, including nephrolithiasis, acute kidney injury, or chronic kidney disease, in patients with overweight or obesity.

If you are using semaglutide for weight management or cardiovascular risk reduction, do not expect it to protect your kidneys. This meta-analysis found no significant impact on renal outcomes like kidney stones or acute kidney injury in overweight or obese patients.

Pharmacological inhibition of Complement C3 using AMY-101 improves healthspan, metabolic fitness, and reduces inflammaging in aged mice.

In aged mice, weekly injections of a C3 inhibitor (AMY-101) improved metabolic health and physical function. This suggests that targeting the complement system could be a viable strategy to combat age-related decline, potentially mimicking the benefits of caloric restriction.

Age-associated elevation of C3a in visceral adipose tissue (VAT) is primarily driven by adipose tissue macrophages (ATMs) via an autocrine ERK-dependent signaling loop.

In aging, fat tissue (specifically visceral fat) becomes a source of inflammation due to immune cells (macrophages) producing complement proteins like C3a. This process is driven by specific signaling pathways within these cells.

Obesity heritability is estimated at 40-70%, driven by over 1000 genetic variants and complex interactions with environmental and epigenetic factors, with early-onset severe obesity strongly linked to specific genetic mutations.

Recognize that obesity has a strong biological basis, with heritability estimates up to 70%. For those with early-onset severe obesity, genetic factors play a major role. This understanding supports the use of targeted therapies and early screening rather than relying solely on lifestyle advice.

Chronic hyperglycemia and oxidative stress induce beta-cell dedifferentiation by altering the balance of PAX4 and ARX gene expression, causing beta-cells to lose insulin-secreting identity and adopt alpha-cell features.

In Type 2 Diabetes, high blood sugar and stress can cause insulin-producing beta-cells to 'forget' their job and turn into glucagon-producing alpha-like cells. This is driven by epigenetic changes to genes like PAX4 and ARX. This loss of identity contributes to worsening blood sugar control, suggesting that therapies aiming to restore beta-cell identity or function could be beneficial.

Tirzepatide attenuates alcohol-induced dopamine release in the nucleus accumbens and induces sustained synaptic depression in the lateral septum.

Tirzepatide's effect on alcohol reward involves reducing dopamine release in the nucleus accumbens and altering synaptic plasticity in the lateral septum.

Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces the risk of heart failure and kidney disease progression in patients with chronic kidney disease and type 2 diabetes.

If you have type 2 diabetes and kidney disease, ask your doctor about finerenone. It helps protect your kidneys and heart from further damage.

Bariatric surgery in older adults (≥65 years) is associated with significantly higher rates of in-hospital mortality and complications compared to younger adults, and should be reserved for refractory cases.

Surgery is the most effective weight loss method but carries higher risks for those over 65. It should only be considered if you have severe obesity and have failed all other treatments, after a thorough risk-benefit discussion with specialists.

Cardiovascular disease (CVD) is the leading cause of death in China, accounting for 36% of deaths.

Healthcare strategies in China should prioritize addressing CVD to reduce mortality.

There has been little attention paid to designs, methods, and analytic techniques for early phase trials in behavioral intervention research.

More focus is needed on innovative designs for early phase trials in behavioral interventions.

No significant associations were found between LCD scores and mortality risk in other racial and ethnic groups.

Practitioners should be aware that LCD scores may not be relevant for mortality risk in non-Hispanic populations.

Despite extensive research, many unknowns remain in the field of nutrition due to the difficulty of studying lifestyle factors in isolation.

Practitioners should remain aware of the complexities and uncertainties in nutrition research.